Explore 3 Stock Ideas & Industry Insights Download Free Report

blue-chip

Eli Lilly (NYSE: LLY): Pricing Pressures, Rising Costs, and Earnings Growth Uncertainty

Oct 29, 2026 | Team Kalkine
Eli Lilly (NYSE: LLY): Pricing Pressures, Rising Costs, and Earnings Growth Uncertainty
Image source: shutterstock

  • LLY:NYSE
  • Investment Type
    Large-cap
  • Risk Level
  • Action
  • Rec. Price (US$)

Eli Lilly and Company (NYSE: LLY)

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company engaged in the discovery, development, manufacturing, and marketing of human medicines. The company operates manufacturing and distribution facilities across the U.S., Puerto Rico, Europe, and Asia, and sells its products in nearly 90 countries. Its portfolio spans cardiometabolic health, oncology, immunology, and neuroscience, with key brands such as Mounjaro, Zepbound, Jardiance, Verzenio, Jaypirca, Ebglyss, Taltz, Omvoh, Emgality, and Kisunla.

As per our previous Global Low Carbon Report published on ‘LLY’ on June 26, 2026, we provided an ‘Buy’ stance on the stock at USD 1127.69 based on “price action, , decent fundamentals, and technical analysis”, the stock has gone up by mere 22.14% and has attained resistance 1 and resistance 2.

Noted below are the details of support and resistance levels provided in our previous report:


Disclaimer-

The advice given by Kalkine Canada Advisory Services Inc. and provided on this website is general information only and it does not take into account your investment objectives, financial situation and the particular needs of any particular person. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. The website www.kalkine.ca is published by Kalkine Canada Advisory Services Inc. The link to our Terms & Conditions has been provided please go through them. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.

Past performance is not a reliable indicator of future performance.

Support

Hi! How can we help you today?

Loading…